Furthermore, these DPP‐4 inhibitors can inhibit the phenotypic transformation of renal microvascular smooth muscle cells and inhibit EndMT by upregulating bone morphogenetic protein receptor 2 and downregulating TGF‐β1, thus reducing renal fibrosis.91 The gene discussed is TGFB1; the disease is renal fibrosis.